Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant trastuzumab + docetaxel ± bevacizumab guided by PET in early HER2-positive breast cancer
2009-013410-26Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab, docetaxel and bevacizumab in breast cancer (3 arms), sponsored by Roche. Primary endpoint: Pathological complete response rate. Started Dec 2009; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-013410-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013410-26.